N(ɛ)-acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors

HDAC inhibitors have been developed very rapidly in clinical trials and even in approvals for treating several cancers. However, there are few reported HDAC inhibitors designed from N(ɛ)-acetyl lysine. In the current study, we raised a novel design, which concerns N(ɛ)-acetyl lysine derivatives cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fang, Wang, Chun, Wang, Jie, Zou, Yefang, Chen, Xiaoxue, Liu, Ting, Li, Yan, Zhao, Yonglong, Li, Yongjun, He, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2019
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599804/
https://www.ncbi.nlm.nih.gov/pubmed/31312496
http://dx.doi.org/10.1098/rsos.190338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599804/
https://www.ncbi.nlm.nih.gov/pubmed/31312496
http://dx.doi.org/10.1098/rsos.190338

Ejemplares similares